Health and Healthcare

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

307 Articles

Chris Lange | Apr 27, 2016 at 8:10 AM EDT

Short Sellers Run for Cover From Major Biotechs

The April 15 short interest data have been compared with the previous report, and short interest decreased across the board…

Lee Jackson | Apr 26, 2016 at 10:05 AM EDT

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy…

Chris Lange | Apr 12, 2016 at 9:55 AM EDT

Short Sellers Run for Cover From Major Biotechs

The March 31 short interest data have been compared with the previous report, and short interest decreased across the board…

Chris Lange | Mar 10, 2016 at 8:05 AM EST

Short Sellers Back Off of Major Biotechs

The February 29 short interest data have been compared with the previous report, and short interest decreased across the board…

Jon C. Ogg | Feb 25, 2016 at 5:15 PM EST

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four…

Chris Lange | Feb 25, 2016 at 8:46 AM EST

Short Interest Rises Across the Board in Major Biotechs

The February 12 short interest data have been compared with the previous report, and short interest increased across the board…

Chris Lange | Feb 10, 2016 at 8:40 AM EST

Major Biotech Short Interest Continues to Be Mixed

The January 29 short interest data have been compared with the previous report, and short interest was mixed in most…

Jon C. Ogg | Feb 4, 2016 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: GoPro, Illumina, Mattel, Match, Peabody, Petrobras, Wayfair, Yahoo and More

The top analyst upgrades, downgrades and initiations seen on Thursday include GoPro, Illumina, Mattel, Match, PeabodyEnergy, Petrobras, Wayfair and Yahoo.

Chris Lange | Jan 28, 2016 at 8:35 AM EST

Short Sellers Increase Bets in Major Biotechs

Short interest increased in most of these selected biotech stocks for the most recent settlement date.

Chris Lange | Jan 13, 2016 at 8:35 AM EST

Short Interest Remains Mixed for Major Biotechs

The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech…

Chris Lange | Dec 28, 2015 at 8:40 AM EST

Short Interest Remains Mixed in Major Biotechs

The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in…

Lee Jackson | Dec 19, 2015 at 10:15 AM EST

Insider Selling Highlights: Cisco, Shake Shack and More (Updated)

Clearly insiders were not in the mood to sell shares this week, and with only two shortened trading weeks left…

Chris Lange | Dec 10, 2015 at 8:40 AM EST

Mixed Views on Major Biotech Short Interest

The November 30 short interest data have been compared with the previous report, and short interest was mixed in these…

Chris Lange | Nov 25, 2015 at 9:06 AM EST

Short Sellers Run for Cover From Major Biotechs

24/7 Wall St. has reviewed the short interest data on the top biotech companies.

Chris Lange | Nov 11, 2015 at 7:45 AM EST

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.

1 … 12 13 14 15 16 … 21

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

Short Sellers Run for Cover From Major Biotechs

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

Short Sellers Run for Cover From Major Biotechs

Short Sellers Back Off of Major Biotechs

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Major Biotech Short Interest Continues to Be Mixed

Top Analyst Upgrades and Downgrades: GoPro, Illumina, Mattel, Match, Peabody, Petrobras, Wayfair, Yahoo and More

Short Sellers Increase Bets in Major Biotechs

Short Interest Remains Mixed for Major Biotechs

Short Interest Remains Mixed in Major Biotechs

Insider Selling Highlights: Cisco, Shake Shack and More (Updated)

Mixed Views on Major Biotech Short Interest

Short Sellers Run for Cover From Major Biotechs

Short Sellers Run for Cover From Major Biotechs

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

Short Sellers Run for Cover From Major Biotechs

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

Short Sellers Run for Cover From Major Biotechs

Short Sellers Back Off of Major Biotechs

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Major Biotech Short Interest Continues to Be Mixed

Top Analyst Upgrades and Downgrades: GoPro, Illumina, Mattel, Match, Peabody, Petrobras, Wayfair, Yahoo and More

Short Sellers Increase Bets in Major Biotechs

Short Interest Remains Mixed for Major Biotechs

Short Interest Remains Mixed in Major Biotechs

Insider Selling Highlights: Cisco, Shake Shack and More (Updated)

Mixed Views on Major Biotech Short Interest

Short Sellers Run for Cover From Major Biotechs

Short Sellers Run for Cover From Major Biotechs

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

Featured Reads

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It